Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 13, 2008 Brian Lawler	Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug.
The Motley Fool February 15, 2008 Brian Lawler	Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for.
The Motley Fool May 10, 2005 Charly Travers	Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in?
The Motley Fool November 16, 2007 Brian Lawler	Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note.
The Motley Fool November 10, 2006 Brian Lawler	Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note.
The Motley Fool January 12, 2004 Dave Marino-Nachison	All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials.
The Motley Fool September 28, 2010 Brian Orelli	It's Up! It's Down! It's Dendreon! The joys of biotech.
The Motley Fool April 30, 2010 Brian Orelli	Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it?
The Motley Fool August 18, 2010 Travers & Greer	Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon?
The Motley Fool May 10, 2006 Brian Lawler	Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note.
The Motley Fool February 7, 2011 Brian Orelli	Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet.
The Motley Fool October 29, 2007 Brian Lawler	World's Scariest Stock: Dendreon Investing in the biotech sector is scary enough for most investors. Dendreon's scary future should makes this stock an under-performer.
The Motley Fool May 3, 2005 Karl Thiel	Is Dendreon a Rule Breaker? In working to bring the first therapeutic cancer vaccine to market, the company has faced numerous unknowns and challenges. At this stage, it has produced a fair bit of data that investors can use to size up the firm's prospects, but ultimately, you're either a believer or you're not.
The Motley Fool September 22, 2010 Brian Orelli	A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead.
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
The Motley Fool April 4, 2008 Brian Lawler	A Few Thoughts on Dendreon Let's talk about the upcoming Dendreon study results.
The Motley Fool June 18, 2009 Daniel Harrison	Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains.
The Motley Fool March 2, 2011 Brian Orelli	When Will Dendreon Make Money? Not for awhile ... it's a biotech thing.
The Motley Fool June 1, 2007 Brian Lawler	Dendreon Gains. Why? Shares of the biopharma rise after it announces already expected news.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool September 29, 2010 Brian Orelli	Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers.
The Motley Fool April 14, 2009 Brian Orelli	Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge.
The Motley Fool August 31, 2010 Brian Orelli	What Is Dendreon Worth? Now that's a good question, isn't it?
The Motley Fool November 18, 2010 Brian Orelli	Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge.
The Motley Fool August 29, 2011 Brian Orelli	We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply.
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
The Motley Fool December 23, 2011 Selena Maranjian	3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick.
The Motley Fool January 7, 2011 Brian Orelli	Dendreon Heads Across the Pond A pathway to Provenge approval in the EU.
The Motley Fool April 3, 2007 Brian Lawler	Dendreon's Positive Panel Surprise Shares of the drugmaker jump after a FDA advisory panel finds in favor of its lead cancer compound.
The Motley Fool September 13, 2007 Brian Lawler	Don't Bet on the Dendreon Lawsuit A patient advocacy group files a lawsuit attempting to usher Dendreon's prostate cancer drug Provenge onto the market after the FDA has withheld approval. Investors should take note.
The Motley Fool November 19, 2010 Brian Orelli	Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all.
The Motley Fool May 14, 2007 Brian Lawler	Dendreon Tries to Pick Up the Pieces Dendreon lays out its preliminary plans following a negative FDA regulatory decision. Investors shouldn't necessarily take the smashed-down share price as indicative of a possible biotech value play.
The Motley Fool April 26, 2007 Mike Havrilla	Dendreon Is Worth a Shot Provenge might be approved, which means investors might be rewarded. However, the massive short interest also highlights the tremendous risk in Dendreon.
The Motley Fool May 16, 2007 Brian Lawler	GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note.
The Motley Fool January 17, 2007 Brian Lawler	Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note.
The Motley Fool April 5, 2010 Brian Orelli	1 Month to Go! Is Dendreon a Buy? Only if you understand the risks.
The Motley Fool April 29, 2009 Brian Orelli	2 Lessons From Dendreon Traders beware.
The Motley Fool August 4, 2010 Brian Orelli	Dendreon Doubles Up The biotech enjoys twice as much revenue month over month.
The Motley Fool November 11, 2010 Brian Orelli	Moderate Results, Moderate Rally for Dendreon Sometimes good enough really is good enough.
The Motley Fool August 10, 2011 Jim Mueller	Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here.
The Motley Fool June 1, 2010 Brian Orelli	Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile.
The Motley Fool December 14, 2007 Brian Lawler	Ignore the Dendreon Hoopla A Congressional probe request will have no effect on Dendreon or Provenge's odds at making it through the FDA, since it was not the FDA reviewers of the Provenge marketing application that were accused of anything bad.
The Motley Fool November 3, 2011 David Williamson	Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100.
The Motley Fool June 5, 2007 Brian Lawler	Dendreon Gets Its Funding Dendreon does a financing to secure its near-term future. Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril.
The Motley Fool May 9, 2007 Brian Lawler	Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note.
The Motley Fool May 3, 2011 Brian Orelli	Brakes Are Off at Dendreon Ramping up sales, one month at a time.
The Motley Fool September 27, 2011 Brian Orelli	Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine.
The Motley Fool December 14, 2010 Brian Orelli	An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis.
The Motley Fool August 8, 2007 Brian Lawler	Dendreon Plods Along The turbulent drug developer releases its second-quarter financial results. Investors, take note.
The Motley Fool April 17, 2007 Matt Koppenheffer	The 5-Sigma Report A look at the stocks that saw serious volatility last week. Dyax... SLM Corp... IPSCO... Dendreon... Manor Care...